Single Center

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

Retrieved on: 
Wednesday, May 8, 2024
ENDO, Molecule, Science, Efficacy, Hyperplasia, ACTH, Safety, CAH, ASD, Policy, Abstract, Serum, Innovation, Lanreotide, Octreotide, Barrow Neurological Institute, Endocrine Society, Single Center, Congenital adrenal hyperplasia, A4, Endocrine system, Pharmaceutical industry

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston, Massachusetts.

Key Points: 
  • One presentation will showcase initial safety and key biomarker efficacy findings in CAH, including rapid and profound reductions in androstenedione (A4) and 17-hydroxyprogesterone levels in participants, from the Phase 2 open label TouCAHn study.
  • A second presentation includes data from a Phase 1b/2a open-label single center study of atumelnant in ACTH-dependent Cushing’s syndrome and will feature the first evidence of rapid and sustained cortisol reductions in participants.
  • Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated.
  • Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

Lupus Foundation of America Research Initiatives to be Presented at the 2022 American College of Rheumatology Annual Meeting

Retrieved on: 
Tuesday, November 8, 2022
Online, Consensus, Review, Proteinuria, Lupus, Human, News, Lupus Foundation of America, Foundation, Social, Antiphospholipid syndrome, Patient, Social support, APS, Blood, Biomarker, Single Center, ACR, LFA, Inflammation, Pregnancy, Disease, Program, American College, SDI, Man, RN, Pain, Education, Doctor of Philosophy, American College of Rheumatology, Importance, Home After Three Months Away, Fair trade impact studies, Improvement, Physical activity, Caregiver, Woman, Salmon, Quality of life, End organ damage, Adult, Time, Pharmaceutical industry, Medicine, Medical device, Person, Rheumatology, Belimumab, Research

WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- The American College of Rheumatology Convergence 2022 meeting will be held in Philadelphia, PA from November 10-14, 2022. The Lupus Foundation of America (LFA) and investigators funded by the Foundation will share novel research findings, as well as program insights from its LupusConnect™ online community.

Key Points: 
  • The Lupus Foundation of America (LFA) and investigators funded by the Foundation will share novel research findings, as well as program insights from its LupusConnect online community.
  • The abstract, LupusConnect: A 24/7 Online Lupus Support Community , presents popular topics discussed by more than 18,000 community members with a self-reported connection to lupus.
  • During the pandemic, community membership and engagement remained strong, underscoring a need for connection within the lupus community.
  • Throughout the ACR Meeting, the LFA will tweet updates on innovative scientific initiatives and research studies presented as well as breaking news.

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Retrieved on: 
Saturday, December 11, 2021
Health, General Health, Instagram, Infection, U.S. Securities and Exchange Commission, LinkedIn, NK, BLA, FDA, Time-invariant system, Lymphatic system, Cell, Population, Hospital, Private Securities Litigation Reform Act, Nominal interest rate, Haematopoiesis, Hematology, UPMC Children's Hospital of Pittsburgh, COVID-19, Cancer, Single Center, HSCT, SEC, Immunotherapy, Breakthrough therapy, Haematopoietic system, Degenerative disease, Safety, NAM, Patient, Therapy, DFS, Immune system, Security (finance), Bone marrow, Orphan, Facebook, Risk, ASH, Twitter, Division, Secondary malignant neoplasm, Society, Duke University, Pharmaceutical industry, Vaccine, Medical imaging, Blood, EU, Omidubicel, Gamida Cell, OMIDUBICEL, GAMIDA CELL

The robust recovery of the immune system provides rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel.

Key Points: 
  • The robust recovery of the immune system provides rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel.
  • Gamida Cell will present additional clinical updates at ASH including two-year survival data for GDA-201, the companys lead NAM-enabled NK cell therapy, and an analysis of hospital and healthcare resource use for patients treated with omidubicel compared to cord blood transplantation.
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with blood cancers.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.

Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Society, Lymphatic system, Cancer, ASH, Single Center, Survival, Hematology, Autoimmunity, Patient, Bio, Toxic leukoencephalopathy, Ruxolitinib, Pharmaceutical industry, Whaling

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for cancer, autoimmune and genetic blood disorders, today announced that new data will be presented from a single-center Phase 2 trial and a multi-center Phase 1b trial at the American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for cancer, autoimmune and genetic blood disorders, today announced that new data will be presented from a single-center Phase 2 trial and a multi-center Phase 1b trial at the American Society of Hematology (ASH) Annual Meeting.
  • Specifically, pooled data from patients treated with Orca-T, an investigational high-precision cell therapy product being studied in patients with hematologic malignancies, will be shared in an oral presentation.
  • Additionally, results of Orca-T in a subset of patients with myelofibrosis from those same trials will be shared in a poster presentation.
  • Details of the Orca Bio presentations follow:
    Orca-T Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Oncology, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Safety, Infection, Therapy, Immunotherapy, Technology, Aplastic anemia, LinkedIn, Cancer, PA, Poster, Twitter, Security (finance), ADCC, U.S. Securities and Exchange Commission, Patient, Hematopoietic stem cell transplantation, Private Securities Litigation Reform Act, FDA, Lymphatic system, Single Center, SEC, Cell, ASH, Duke University Hospital, NAM, Cleveland Clinic, UPMC, Risk, Instagram, Clinical trial, Trial of the century, Facebook, COVID-19, EST, NK, Bone marrow, Division, Department, Society, Pharmaceutical industry, Vaccine, Medical imaging, Omidubicel, GDA-201, Gamida Cell, OMIDUBICEL, GDA-201, GAMIDA CELL

Together the data that will be presented at ASH reflect the progress across Gamida Cells NAM-enabled pipeline of cell therapies being developed as potentially curative approaches for cancer patients in need of new and better therapeutic options.

Key Points: 
  • Together the data that will be presented at ASH reflect the progress across Gamida Cells NAM-enabled pipeline of cell therapies being developed as potentially curative approaches for cancer patients in need of new and better therapeutic options.
  • GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results, as reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition1.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.